A Phase 3 study evaluating retatrutide (LY3437943) in participants with obesity and cardiovascular disease (CVD) reached its primary completion on 2026-04-16. This milestone for trial NCT05882045 indicates that data collection for the primary endpoint has concluded.
Background
Retatrutide (LY3437943) is an investigational drug being studied for its therapeutic potential in individuals diagnosed with obesity, a chronic and complex disease characterized by excessive body fat, and those with established cardiovascular disease (CVD). The presence of both conditions often complicates patient management and increases health risks. This Phase 3 study is designed to rigorously evaluate the efficacy and safety profile of retatrutide in this specific, high-need patient population.
Trial design
The Phase 3 study, identified as NCT05882045, carries the full title "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease." This large-scale trial enrolled a total of 1946 participants. Its primary objective is to evaluate the efficacy and safety of retatrutide when administered once weekly to participants who have both obesity and established cardiovascular disease. The study design includes comparator arms, with participants receiving either retatrutide or placebo. The overall duration of the study is approximately 113 weeks. While the specific primary outcome measures were not detailed in the provided data, the trial aims to provide comprehensive data on the drug's performance in this challenging patient group.
What this means
The announcement of primary completion for this Phase 3 study of retatrutide represents a significant developmental milestone. For patients living with obesity and co-existing cardiovascular disease, the availability of new, effective treatment options is highly anticipated. Primary completion means that the collection of data relevant to the trial's main objective has been finalized. Researchers will now proceed with the extensive process of data analysis, interpretation, and eventual reporting of the study's findings. These forthcoming results will be critical for understanding retatrutide's potential role in clinical practice, informing regulatory decisions, and ultimately impacting treatment strategies for a population with significant unmet medical needs. The scientific and medical communities, along with patient advocates, will closely monitor for the release of these comprehensive efficacy and safety data.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05882045, titled "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease," was updated with this status on 2026-04-16 on clinicaltrials.gov.